Incannex Healthcare Azioni (NASDAQ: IXHL)

Ultime notizie per Incannex Healthcare (NASDAQ:IXHL) Azioni

Incannex Healthcare

Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.

Incannex Healthcare Inc

WIIM

REYN

Reynolds Consumer Products shares are trading higher after the company reported better-than-expected Q2 financial results.

Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) <a target="_blank" href="https://www.benzinga.com/tech" rel="noreferrer noopener">has agreed to pay</a> The New York Times (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYT#NYSE">NYT</a>) between $20 million and $25 million annually under a multiyear content licensing deal, according to people familiar with the terms.
Though the companies announced the agreement in May, this is the first time financial details have come to light.
The annual payout represents nearly 1% of the Times&#8217;s 2024 revenue and offers insight into how major tech firms are valuing journalism in an AI-driven information landscape, the Wall Street Journal <a target="_blank" href="https://www.wsj.com/business/media/amazon-to-pay-new-york-times-at-least-20-million-a-year-in-ai-deal-66db8503" rel="noreferrer noopener">reported</a> on Wednesday.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/23/12/36236482/googles-ai-search-a-double-edged-sword-for-publishers-like-the-atlantic" rel="noreferrer noopener">Google&#8217;s AI Search &#8211; A Double-Edged Sword for Publishers Like the Atlantic</a>
The deal gives Amazon access to a wide range of New York Times content including material from its core news site, cooking section, and The Athletic, which Amazon can use to train AI models and power features like Alexa responses, including summaries or snippets from Times stories.
This marks Amazon&#8217;s first AI-related licensing agreement with a news publisher and The Times&#8217;s first deal with a tech giant for AI training purposes, the WSJ writes.
<h2 class="wp-block-heading">Other AI-Content Partnerships</h2>
As AI tools increasingly compete with traditional search engines and draw traffic away from publisher websites, licensing deals have emerged for media companies to monetize their content.
OpenAI, for instance, <a target="_blank" href="https://www.benzinga.com/news/24/05/38975543/news-corp-stock-pops-on-multiyear-deal-with-openai" rel="noreferrer noopener">has signed similar pacts</a>, including one with News Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWS#NASDAQ">NWS</a>) that could be worth more than $250 million over five years, and another with Axel Springer valued at $25 million to $30 million over three years.
OpenAI and Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) formed a partnership that granted ChatGPT access to Reddit threads and introduced new AI-powered features for Reddit users.
According to the May 2023 report, the New York Times <a target="_blank" href="https://www.benzinga.com/news/23/05/32281165/google-to-dole-out-100m-to-new-york-times-under-multi-year-content-deal" rel="noreferrer noopener">earned nearly $100 million</a> over three years from a deal with Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google that allowed the tech giant to feature Times content across its platforms.
The expanded agreement covered content distribution, subscriptions, and using Google tools for marketing and ad testing. It helped offset lost revenue after Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) chose not to renew its Facebook News tab deal, which previously paid the Times over $20 million annually.
Meanwhile, News Corp also struck a multiyear deal with Google in 2021, estimated to bring in over $100 million annually. Both media companies have criticized Google and Facebook for using news content without fair compensation.
Price Actions: NYT shares are down 0.18% at $51.91 at the last check Wednesday. AMZN is down 0.36%.
Also Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/07/46668574/alphabets-legal-woes-may-create-buying-opportunity-analyst" target="_blank" rel="noreferrer noopener">Google Parent Alphabet&#8217;s Legal Woes May Create Buying Opportunity: Analyst</a></li>
</ul>
Photo by Tada Images via Shutterstock

News

Tech

Media

AMZN

GOOGL

RDDT

New York Times Gets New AI Partner For $20-$25 Million

HC Wainwright &amp; Co. analyst Joseph Pantginis downgrades VYNE Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) from Buy to Neutral.

Downgrades

Analyst Ratings

VYNE

HC Wainwright & Co. Downgrades VYNE Therapeutics to Neutral

UBS analyst Michael Ward maintains Unum Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNM#NYSE">UNM</a>) with a Neutral and lowers the price target from $91 to $87.

Price Target

UBS Maintains Neutral on Unum Gr, Lowers Price Target to $87

Olin shares are trading lower after Wells Fargo and Keybanc cut their respective price targets on the stock.

EXLS

ExlService Holdings shares are trading higher after the company reported better-than-expected Q2 financial results, raised its FY25 guidance, and announced a $125 million share repurchase program.

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has been riding through a rough patch. Between Elon Musk's growing list of distractions, intensifying Chinese EV competition, a public feud with President Donald Trump, and a steep drop in global EV demand, the company has watched its sales shrink and its stock underperform the <a href="https://www.benzinga.com/tech">broader tech rally</a>.
<ul class="wp-block-list">
<li>Check Tesla&#8217;s stock performance <a href="https://www.benzinga.com/quote/TSLA">here</a>.</li>
</ul>
Now, Musk is trying to reverse course with what looks like a full-scale reboot.
Read Also: <a href="https://www.benzinga.com/markets/tech/25/07/46273662/no-plan-b-teslas-musk-premium-is-on-thin-ice">No Plan B &#8211; Tesla&#8217;s Musk Premium Is On Thin Ice</a>
<h2 class="wp-block-heading">Robotaxis, AI, And A Budget EV: Tesla's New Playbook</h2>
At the center of Tesla's comeback plan is a trio of high-risk, high-reward bets: a Robotaxi rollout in Texas, the introduction of an approximately $25,000 EV aimed at mass affordability, and deeper integration of AI features through its xAI arm. Adding muscle to the plan is a <a href="https://www.benzinga.com/markets/tech/25/07/46651922/samsung-inks-decade-long-16-5-billion-chip-manufacturing-pact-with-mystery-tech-giant-as-it-fights-to-regain-ground-from-tsmc">$16.5 billion chip deal with Samsung</a>—intended to supercharge Tesla's autonomous ambitions.
Mo Sparks, chief product officer at Direxion, sees the Samsung deal as a signal Tesla is doubling down on its original tech-first promise. "It's a signal of confidence and potential acceleration in Tesla's roadmap towards autonomous vehicles, robotics and AI," Sparks told Benzinga in exclusive comments shared over email.
<h2 class="wp-block-heading">Bulls And Bears Dig In—With Leverage</h2>
Tesla bulls are leaning into leveraged exposure via the Direxion Daily TSLA Bull 2X Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSLL#NYSE">TSLL</a>), betting that the combination of robotaxis, affordable EVs, and AI integration can reignite growth.
But bears remain firm in their view that this is another Musk spectacle lacking operational substance. Sparks notes, "This partnership doesn't settle any debates—it just adds fuel to each side's conviction." For skeptics expecting more downside, the Direxion Daily TSLA Bear 1X Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSLS#NYSE">TSLS</a>) remains their weapon of choice.
With its identity—and valuation—on the line, Tesla's latest chapter could either mark a visionary turnaround or another expensive misfire. Investors are watching closely—and taking sides.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46662067/elon-musks-30-trillion-bombast-may-come-back-to-haunt-tesla-bulls">Elon Musk&#8217;s $30 Trillion Bombast May Come Back To Haunt Tesla Bulls</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Trading Ideas

TSLA

TSLL

TSLS

Pushed To The Brink, Tesla Is Gambling On A Make-Or-Break Reboot

BURBANK, Calif., July 30, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4477974-1&amp;h=2749086386&amp;u=https%3A%2F%2Furldefense.com%2Fv3%2F__https%3A%2Fwww.cj4dx.com%2F__%3B!!N96JrnIq8IfO5w!hAZTO4n4FnhcziU0p8PHj6zGs89qcMQxi3yTpqfsDq1Rke7XjclMLmXE6D2-xuMiKv-NRfYza_rFQiK1Jkjtatdu7oMg%24&amp;a=CJ+4DPLEX">CJ 4DPLEX</a>, the world's leading producer of premium film formats and cinema technologies, and Cinemark, one of the largest and most influential theatrical exhibition companies in the world, today announced an expansion of their existing relationship with the addition of 20 new SCREENX locations across theaters in the U.S. and Latin America.
 Of the 20 new locations, 18 will open across the United States, with six slated to open in 2025 and the remaining set to debut in 2026. As a leading exhibitor in the Latin American market, Cinemark will introduce SCREENX to audiences in the region for the first time, with theaters scheduled to open next year.
SCREENX, the world's first multi-projection cinema technology, surrounds moviegoers with a dynamic 270-degree panoramic field of view. By extending key scenes onto the left and right walls of the auditorium, it creates immersive, story-enhancing visuals that naturally fill the viewer's peripheral vision and pull them deeper into the film.
"SCREENX is a distinctive premium format that enhances the moviegoing experience by expanding storytelling across our immersive auditorium screens," said Damian Wardle, Cinemark's EVP, Theater &amp; Technology Operations. "We are excited to deepen our collaboration with CJ 4DPLEX and bring even more cutting-edge cinematic experiences to our guests, including, for the first time, audiences in Latin America."
Don Savant, CEO of CJ 4DPLEX Americas,&nbsp;stated, "With this deal, Cinemark reinforces their commitment to being one of the most influential theatrical exhibition companies in the world. Together, we're not just expanding more theaters, we're revolutionizing how moviegoers watch cinema with our truly differentiated SCREENX format.&nbsp;We're excited to broaden our footprint in the United States, introduce SCREENX to Cinemark's Latin American patrons for the first time, and continue pushing the boundaries of&nbsp;the cinematic experience."&nbsp;
CJ 4DPLEX and Cinemark first partnered in 2022 with the launch of their initial SCREENX locations in California and Texas. The success of these theaters, driven by strong audience demand for premium formats, laid the foundation for the expanded agreement.

General

Cinemark And CJ 4DPLEX Expand Their Existing Relationship With The Addition Of 20 New SCREENX Locations Across Theaters In The U.S. And Latin America

BWS Financial analyst Hamed Khorsand maintains TriMas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRS#NASDAQ">TRS</a>) with a Buy and raises the price target from $40 to $45.

BWS Financial Maintains Buy on TriMas, Raises Price Target to $45

SITE

SiteOne Landscape Supply shares are trading higher. The company reported Q2 financial results.

UBS analyst Mark Carden maintains Sysco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYY#NYSE">SYY</a>) with a Buy and lowers the price target from $91 to $90.

UBS Maintains Buy on Sysco, Lowers Price Target to $90

As Social Security reaches its 90th anniversary, a new <a href="https://www.aarp.org/content/dam/aarp/research/topics/work-finances-retirement/social-security/social-security-90th-anniversary-survey.doi.10.26419-2fres.00976.001.pdf">survey</a> from AARP shows that nearly all Americans — regardless of age or political affiliation — see the program as a vital part of financial security. And compared to just five years ago, many say it's more important than ever.
<h2 class="wp-block-heading">Broad Support Across Political Lines</h2>
According to the survey, 96% of Americans say <a href="https://www.benzinga.com/personal-finance/management/25/07/46559438/he-lost-his-wife-and-now-hes-been-waiting-over-6-months-for-her-social-security-benefits">Social Security</a> is important. That figure includes 98% of Democrats, 95% of Republicans, and 93% of Independents. Support remains strong across all age groups, not just among those nearing or in retirement.
The survey also found that 67% of respondents believe Social Security is more important now than it was five years ago. That's up from previous surveys conducted in 2020 and 2015.
Don't Miss:
<ul class="wp-block-list">
<li>Accredited Investors: Grab Pre-IPO Shares of the AI Company Powering Hasbro, Sephora &amp; MGM—<a href="https://www.benzinga.com/money/rad-intel">Just $0.63 Before NASDAQ Launch</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
<h2 class="wp-block-heading">A Cornerstone of Retirement Security</h2>
For many <a href="https://www.benzinga.com/personal-finance/management/25/07/46617685/people-think-they-need-4-million-to-retire-comfortably-can-you-guess-how-many-really-have-that-much">Americans in retirement</a>, Social Security is a key source of income. Nearly two-thirds of retired respondents say they rely heavily on it, while another 21% say they rely on it somewhat. This marks a steady increase from 58% in 2010, showing how the program's role in retirement planning has expanded over time.
In New Jersey, for example, over 1.7 million people rely on Social Security benefits, with more than 596,000 families counting on it for over half their household income, according to AARP.
Social Security doesn't just help with bills — it offers retirees the freedom to pursue hobbies, spend time with loved ones, or simply take a well-earned break.&nbsp;
"The survey findings reinforce Social Security's reputation for being one of the most successful and popular initiatives in American history, helping generations of older New Jerseyans stay out of poverty and live with dignity after a lifetime of hard work," says AARP New Jersey State Director Chris Widelo.&nbsp;
Trending: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can <a href="https://www.benzinga.com/money/mode-mobile-2">invest today for just $0.30/share.</a>
<h2 class="wp-block-heading">Concerns About the Future</h2>
Despite broad support, confidence in Social Security's future is slipping. Only 36% of Americans say they feel confident the program will be there for them — a seven-point drop from 2020. Younger adults in particular express uncertainty about whether Social Security will be sufficient by the time they retire.
In fact, 78% of respondents worry that their benefits won't be enough to live on. That's up from 74% in 2020. Meanwhile, 62% say the average monthly payment — currently about $2,000 — is too low.
Even though many believe they understand how the system works, the report shows that most Americans may not have all the knowledge they need to make informed decisions about <a href="https://www.benzinga.com/personal-finance/25/04/44657139/suze-orman-says-stop-collecting-social-security-early-because-you-could-be-sabotaging-your-financial-future">when to start collecting benefits</a>.
See Also: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a>
<h2 class="wp-block-heading">A Promise Worth Keeping</h2>
While confidence in the system's future may be declining, belief in its purpose remains strong. AARP found that 89% of Americans believe Social Security allows older adults to remain independent and avoid relying on family for financial support.
The same percentage agree that without Social Security, those who need it most would suffer financially. And support for the core values behind Social Security — fairness, shared responsibility, and honoring promises — continues to be high.
As America marks 90 years of Social Security, the survey makes one thing clear: people still see it as a vital contract between generations — one that needs to be protected and preserved.
Read Next: Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>
Image: Shutterstock

Personal Finance

Survey: 96% of Americans Say Social Security Is Important — And It's Even More Crucial Than 5 Years Ago

Scotts Miracle-Gro shares are trading lower after the company reported worse-than-expected Q3 revenue results.

UBS analyst Batya Levi maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Buy and lowers the price target from $895 to $850.

SPOT

UBS Maintains Buy on Spotify Technology, Lowers Price Target to $850

Newmont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) has outperformed the market over the past 10 years by 2.71% on an annualized basis producing an average annual return of 14.47%. Currently, Newmont has a market capitalization of $69.73 billion. 
Buying $100 In NEM: If an investor had bought $100 of NEM stock 10 years ago, it would be worth $385.78 today based on a price of $63.48 for NEM at the time of writing.
<h3>Newmont's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753888513_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) will release earnings results for the second quarter, after the <a href="https://www.benzinga.com/quote/HOOD/earnings">closing bell on Wednesday, July 30.</a>
Analysts expect the Menlo Park, California-based company to report quarterly earnings at 35 cents per share, up from 30 cents per share in the year-ago period. Robinhood projects to report quarterly revenue at $913.33 million, compared to $682 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
The company has beaten analyst estimates for revenue in two straight quarters and seven of the last 10 quarters overall.
Robinhood shares fell 3.2% to close at $103.32 on Tuesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/hood/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Piper Sandler analyst Patrick Moley maintained an Overweight rating and increased the price target from $70 to $110 on July 15, 2025. This analyst has an accuracy rate of 89%.</li>
<li>Morgan Stanley analyst Michael Cyprys maintained an Equal-Weight rating and raised the price target from $43 to $110 on July 15, 2025. This analyst has an accuracy rate of 68%.</li>
<li>JMP Securities analyst Devin Ryan maintained a Market Outperform rating and increased the price target from $70 to $125 on July 14, 2025. This analyst has an accuracy rate of 85%.</li>
<li>Barclays analyst Benjamin Budish maintained an Overweight rating and raised the price target from $57 to $102 on July 10, 2025. This analyst has an accuracy rate of 83%.</li>
<li>Citigroup analyst Christopher Allen maintained a Neutral rating and increased the price target from $50 to $100 on July 7, 2025. This analyst has an accuracy rate of 78%.</li>
</ul>
Considering buying HOOD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="624" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30044023/image-472-1024x624.png" alt="" class="wp-image-1006611" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30044023/image-472-1024x624.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30044023/image-472-300x183.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30044023/image-472-768x468.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30044023/image-472.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46684052/jim-cramer-prefers-this-financial-stock-over-brighthouse-financial">Jim Cramer Prefers This Financial Stock Over Brighthouse Financial</a></li>
</ul>

Earnings

Markets

HOOD

Robinhood Likely To Report Higher Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

O-I Glass shares are trading lower following Q2 reported financial results.

Shares of UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) remained volatile in early trading on Wednesday, after a <a href="https://www.benzinga.com/markets/earnings/25/07/46674619/cadence-design-systems-beats-q2-earnings-estimates-raises-fy25-outlook-citing-broad-based-strength-ai-tailwinds">downbeat second-quarter report</a>.
Here are some key analyst takeaways.
<ul class="wp-block-list">
<li>Piper Sandler <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/613f2550b4035700018da9d8/jessica-tassan">analyst Jessica Tassan</a> maintained an Overweight rating, while reducing the price target from $353 to $317.</li>
<li>KeyBanc Capital Markets analyst Matthew Gillmor maintained an Overweight rating, while cutting the price target from $400 to $350.</li>
<li>Oppenheimer <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/584847d8ee7bf6000154d222/michael-wiederhorn">analyst Michael Wiederhorn</a> reaffirmed an Outperform rating, while lowering the price target from $400 to $325.</li>
</ul>
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Piper Sandler: UnitedHealth provided "unprecedented transparency into business mix, earnings drivers and pricing assumptions/ cost trends across UHC and Optum," Tassan said in a note. Management reinstated its full-year guidance. 
Adjusted earnings of $16 per share are shy of the $18-$19 per share consensus.
The company seems to have diagnosed its problems and established "a de-risked path to remediation," the analyst stated. This will likely allow it to generate high-teens adjusted earnings growth in 2026 and 2027. UnitedHealth revised LT target operating margins for UHC&#8217;s Medicare business from 3.00-5.00% to 2.00-4.00%; and revised LT target operating margins at Optum Health from 8.00-10.00% to 6.00-8.00%," she further wrote.
KeyBanc Capital Markets: UnitedHealth Group's medical loss ratio of 89.4% marked a 430 basis points year-on-year improvement, Gillmor said. Optum Insight generated revenue of $5.2 billion, in-line with expectations, despite $1.2 billion of unfavorable items, he added.
"Optum Health continues to be impacted by known pressures, including higher costs, v28, and new member mix," the analyst wrote. The company's earnings guidance may have been disappointing, but established "a credible floor," he further stated.
Oppenheimer: UnitedHealth reinstated its 2025 guidance, with adjusted earnings projected at $16 or more, Wiederhorn said. This could "prove to be trough earnings, as it returns to growth in 2026 and beyond," he added.
"The 2025 guidance assumes the bottom-end or below target ranges across Medicare, Medicaid, Commercial, and OptumHealth, but should improve dramatically over the next two years as it re-prices the respective books," the analyst further wrote.
UNH Price Action: Shares of UnitedHealth Group had risen by 0.61% to $262.65 at the time of publication on Wednesday.
Read More:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46111337/micron-ceo-cautions-ai-boom-may-not-be-fully-sustainable-flags-tariff-driven-demand-pull-in">UnitedHealth Hit By $6.5 Billion Medical Cost Blowout: Launches AI-Led Overhaul, Drops 600K Members To Regain Margins — &#8216;These Are Serious Challenges&#8217;</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings Misses

Reiteration

UnitedHealth Prognosis Mixed: Analysts Trim Targets But Keep Faith After Q2 Miss

Politics

Global

SCCO

Reuters Cites Southern Copper Executive Saying We Maintain Positive Long-Term Outlook For Copper, But Believe Intense U.S.-China Trade War Will Affect Economic Growth Worldwide

CHEF

The Chefs' Warehouse shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 sales guidance.

Press Releases

Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results

Health Care

Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance

Management

Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program

Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

Incannex Healthcare Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy

Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X

Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch

Power Metallic (TSXV: PNPN | OTCQB: PNPNF) Confirms PGE-Copper Discovery at Lion – High Recovery Potential – More Stocks Inside

Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo

Comments

Incannex Healthcare

Notizie

Ultime notizie per Incannex Healthcare (NASDAQ:IXHL) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO